Can Jiang, MD
Family Practice · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 2
Offices
2 locations · Indian Health Center of Santa Clara Valley · Stanford Health Care
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Jiang’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A138424 · Current
Licensed to practise in California · since 2015 · expires 2027-09-30 · University of Illinois College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$7,101
Medicare paid this office $7,101 for 66 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 34 | $2,318 | $68 |
| Short return visit (20+ min) | 12 | $914 | $61 |
| Return visit (30+ min) | 11 | $620 | $52 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 15 | $240 | $15 |
Who their Medicare patients are
66 Original Medicare patients in 2024. Average age 72 · Women 71% · Also on Medicaid 24% · Health risk score 1.02. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 55% · Diabetes 27%.
The office billed $57,744, Medicare allowed $9,366 and paid $7,101; for 132 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 66 | 132 | 72 | 1.02 | $57,744 | $7,101 |
| 2023 | 69 | 146 | 73 | 1.07 | $66,699 | $7,870 |
| 2022 | 58 | 135 | 72 | 0.92 | $70,543 | $8,697 |
| 2021 | 56 | 136 | 72 | 1.23 | $75,577 | $10,742 |
| 2020 | 78 | 146 | 71 | 1.25 | $59,459 | $9,648 |
| 2019 | 50 | 75 | 69 | 1.28 | $13,199 | $4,836 |
| 2018 | 68 | 136 | 70 | 1.84 | $15,389 | $8,885 |
| 2017 | 23 | 27 | 67 | 1.79 | $2,723 | $1,903 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Return visit (30+ min) | 38 | $3,133 | $53 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 35 | $2,018 | $58 |
| Short return visit (20+ min) | 21 | $1,617 | $51 |
2022: 3 services
| Return visit (30+ min) | 30 | $2,803 | $61 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 31 | $2,056 | $66 |
| Short return visit (20+ min) | 17 | $964 | $51 |
2021: 3 services
| Return visit (30+ min) | 30 | $4,510 | $68 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 29 | $2,679 | $92 |
| Short return visit (20+ min) | 17 | $947 | $53 |
2020: 3 services
| Return visit (30+ min) | 46 | $4,692 | $64 |
| Short return visit (20+ min) | 29 | $1,424 | $42 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $475 | $37 |
2019: 2 services
| Return visit (30+ min) | 27 | $2,051 | $57 |
| Short return visit (20+ min) | 21 | $687 | $31 |
2018: 4 services
| Return visit (30+ min) | 35 | $3,111 | $58 |
| New patient visit (45+ min) | 17 | $1,652 | $97 |
| Return visit (30+ min) | 15 | $1,130 | $71 |
| Short return visit (20+ min) | 18 | $783 | $44 |
Medicaid work
$10,185 in 2024
Medicaid paid $10,185 for 63 billed services this clinician did in 2024, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 40 | $10,021 |
| Short return visit (20+ min) | 23 | $164 |
| 2024 | 63 | 2 | 21 | $10,185 |
| 2023 | 39 | 1 | 14 | $9,523 |
| 2021 | 137 | 3 | 49 | $15,383 |
| 2020 | 39 | 1 | 15 | $9,136 |
| 2019 | 430 | 2 | 54 | $59,981 |
| 2018 | 241 | 2 | 50 | $42,301 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 39 | $9,523 |
2021
| Clinic visit/encounter, all-inclusive | 65 | $15,276 |
| Short return visit | 25 | $66 |
| Short return visit (20+ min) | 47 | $41 |
2020
| Clinic visit/encounter, all-inclusive | 39 | $9,136 |
2019
| Clinic visit/encounter, all-inclusive | 262 | $59,243 |
| Short return visit (20+ min) | 168 | $738 |
2018
| Clinic visit/encounter, all-inclusive | 185 | $41,098 |
| Short return visit (20+ min) | 56 | $1,203 |
Drugs they prescribed that Part D paid
$36,553
Pharmacies billed $36,553 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
348 generic and 55 brand-name prescriptions · $36,553 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rosuvastatin | 29 | $1,016 | $35 |
| Alendronate | 18 | $230 | $13 |
| Atorvastatin | 29 | $218 | $8 |
| Fluticasone Propionate | 13 | $173 | $13 |
| Losartan | 15 | $151 | $10 |
See all 8 drugs
| Rosuvastatin | 29 | $1,016 | $35 |
| Alendronate | 18 | $230 | $13 |
| Atorvastatin | 29 | $218 | $8 |
| Fluticasone Propionate | 13 | $173 | $13 |
| Losartan | 15 | $151 | $10 |
| Metformin | 18 | $147 | $8 |
| Amlodipine Besylate | 21 | $100 | $5 |
| Lisinopril | 15 | $47 | $3 |
Year by year
| 2024 | 415 | 67 | None | 13% | $36,553 |
| 2023 | 614 | 83 | 2% (13) | 15% | $85,259 |
| 2022 | 544 | 66 | None | None | $66,405 |
| 2021 | 557 | 83 | None | None | $52,789 |
| 2020 | 491 | 83 | 2% (11) | 9% | $36,232 |
| 2019 | 419 | 67 | None | 14% | $38,813 |
| 2018 | 331 | 63 | 3% (11) | None | $16,040 |
| 2017 | 243 | 50 | 6% (15) | 10% | $11,683 |
| 2016 | 260 | 52 | 13% (33) | None | $13,222 |
| 2015 | 18 | None | None | None | $1,237 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Trulicity | 13 | $12,712 | $978 |
| Rosuvastatin | 40 | $1,401 | $35 |
| Estradiol | 11 | $1,377 | $125 |
| Atorvastatin | 47 | $1,014 | $22 |
| Metformin | 33 | $750 | $23 |
| Amlodipine Besylate | 29 | $573 | $20 |
| Lisinopril | 19 | $500 | $26 |
| Losartan | 26 | $327 | $13 |
| Metformin Hcl Er | 11 | $297 | $27 |
| Alendronate | 15 | $239 | $16 |
| Levothyroxine | 16 | $231 | $14 |
2022: 13 drugs
| Trulicity | 18 | $16,876 | $938 |
| Jardiance | 11 | $10,049 | $914 |
| Rosuvastatin | 32 | $754 | $24 |
| Atorvastatin | 43 | $657 | $15 |
| Metformin | 28 | $607 | $22 |
| Losartan | 31 | $408 | $13 |
| Amlodipine Besylate | 34 | $406 | $12 |
| Metoprolol | 23 | $322 | $14 |
| Lisinopril | 21 | $297 | $14 |
| Alendronate | 20 | $248 | $12 |
| Fluticasone Propionate | 11 | $205 | $19 |
| Levothyroxine | 11 | $201 | $18 |
| Simvastatin | 12 | $173 | $14 |
2021: 14 drugs
| Atorvastatin | 43 | $920 | $21 |
| Rosuvastatin | 31 | $847 | $27 |
| Amlodipine Besylate | 43 | $724 | $17 |
| Pantoprazole | 17 | $303 | $18 |
| Omeprazole | 14 | $298 | $21 |
| Losartan | 32 | $258 | $8 |
| Metoprolol | 22 | $225 | $10 |
| Levothyroxine | 12 | $170 | $14 |
| Sertraline | 15 | $157 | $10 |
| Finasteride | 13 | $153 | $12 |
| Alendronate | 14 | $144 | $10 |
| Metformin | 23 | $139 | $6 |
| Lisinopril | 20 | $118 | $6 |
| Trazodone | 13 | $31 | $2 |
2020: 10 drugs
| Rosuvastatin | 37 | $1,109 | $30 |
| Amlodipine Besylate | 38 | $529 | $14 |
| Atorvastatin | 37 | $494 | $13 |
| Losartan | 15 | $213 | $14 |
| Prednisone | 13 | $213 | $16 |
| Atenolol | 12 | $210 | $18 |
| Gabapentin | 14 | $170 | $12 |
| Lisinopril | 24 | $146 | $6 |
| Metformin | 19 | $137 | $7 |
| Simvastatin | 12 | $97 | $8 |
2019: 8 drugs
| Rosuvastatin | 25 | $622 | $25 |
| Atorvastatin | 30 | $574 | $19 |
| Amlodipine Besylate | 41 | $460 | $11 |
| Lisinopril | 26 | $207 | $8 |
| Metformin | 19 | $178 | $9 |
| Levothyroxine | 11 | $172 | $16 |
| Atenolol | 12 | $114 | $10 |
| Losartan | 11 | $101 | $9 |
2018: 8 drugs
| Atorvastatin | 17 | $632 | $37 |
| Metoprolol | 14 | $429 | $31 |
| Levothyroxine | 16 | $274 | $17 |
| Simvastatin | 15 | $177 | $12 |
| Amlodipine Besylate | 21 | $140 | $7 |
| Lisinopril | 17 | $119 | $7 |
| Hydrochlorothiazide | 16 | $102 | $6 |
| Metformin | 11 | $65 | $6 |
2017: 4 drugs
| Tamsulosin | 19 | $254 | $13 |
| Alendronate | 17 | $142 | $8 |
| Ranitidine | 11 | $116 | $11 |
| Metoprolol | 11 | $34 | $3 |
2016: 4 drugs
| Morphine Sulfate Er | 18 | $1,586 | $88 |
| Hydrocodone-Acetaminophen | 12 | $218 | $18 |
| Pravastatin | 18 | $185 | $10 |
| Lisinopril | 19 | $93 | $5 |
Professional record
- NPI
- 1629482781
- Licence
- CA A138424California A138424: Current · expires 2027-09-30
- Group
- Indian Health Center of Santa Clara Valley · Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-06-17
- NPI last updated
- 2026-08-14
- NPI record certified
- 2026-08-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 211 Quarry Rd, Palo Alto, CA, 94304 · 455 Oconnor Dr Ste 200, San Jose, CA, 95128